<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003414</url>
  </required_header>
  <id_info>
    <org_study_id>J9726 CDR0000066427</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>JHOC-97080106</secondary_id>
    <secondary_id>JHOC-9726</secondary_id>
    <secondary_id>NCI-V98-1453</secondary_id>
    <nct_id>NCT00003414</nct_id>
  </id_info>
  <brief_title>Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease</brief_title>
  <official_title>Randomized Trial of Autologous GVHD for Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an
      immune response that will kill cancer cells. Interleukin-2 and interferon gamma may enhance
      the effectiveness of graft-versus-host disease to kill cancer cells.

      PURPOSE: Randomized phase III trial to determine the effectiveness of graft-versus-host
      disease in treating patients who have recurrent or refractory lymphoma or Hodgkin's disease .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether autologous graft versus host disease significantly alters
      the relapse rate for lymphoma or Hodgkin's disease after autologous bone marrow
      transplantation.

      OUTLINE: This is a randomized study. Stem cells are harvested and cryopreserved. All patients
      receive busulfan/cyclophosphamide or cyclosporine/total body irradiation as a preparative
      regimen. Arm I: Patients randomized to the graft versus host disease (GVHD) induction arm
      receive oral cyclosporine twice a day beginning on day 0 and continuing for at least 28 days,
      followed by peripheral blood stem cell (PBSC) infusion. At the time the white blood cell
      count begins to recover, subcutaneous interferon gamma is administered for 10 doses, followed
      2 days later by subcutaneous interleukin-2 (IL-2) for 18 doses. Arm II: Patients do not
      receive autologous GVHD therapy after the PBSC transplant. Both arms should receive radiation
      to the site of lymphoma after recovering from the stem cell transplantation. Patients are
      followed at 6 months, 1 year, and 2 years posttransplant.

      PROJECTED ACCRUAL: Approximately 50 patients (25 per arm) will be accrued for this study
      within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate for lymphoma after autologous transplant</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon gamma</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Patients receiving autologous or syngeneic peripheral blood stem
        cell transplants for chemotherapy refractory or recurrent lymphoma or Hodgkin's disease,
        including: Progressive disease within 6 weeks of completing initial induction therapy OR
        Failure to achieve at least an overall partial response (at least a 50% reduction in tumor
        size) to conventional salvage therapy following relapse

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: No capillary leak syndrome Hepatic: Bilirubin no greater than
        5 mg/dL Renal: Creatinine less than 4 mg/dL No renal failure requiring dialysis
        Cardiovascular: No hypotension No severe venooclusive disease Pulmonary: No pulmonary
        infiltrates OR No requirement for greater than 2 L oxygen Other: No weight gain greater
        than 5% of baseline weight No concurrent sepsis No temperature of 39 degrees C or higher
        for two or more days No clinically evident ascites

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Prior chemotherapy allowed Endocrine therapy: Not specified Radiotherapy:
        Not specified Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgia B. Vogelsang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bola√±os-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-91. Epub 2007 Aug 3.</citation>
    <PMID>17889355</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>December 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2003</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2015</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

